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INTRODUCTION 1	
 2	
Over the last decade, increasing mortality and morbidity associated with opioid analgesics 3	
has led to concerns about misuse and abuse of these drugs, even when obtained via 4	
prescription.  This has been most pronounced in the United States of America (USA) where 5	
dispensed prescriptions increased from 47 million in 2006 to 60 million in 2013 [11].  This 6	
was accompanied by increases in opioid-related overdose mortality and admission for 7	
treatment [22].  Policies designed to counter these trends have had some effect , with 8	
diversion, abuse, and attributable mortality reaching a plateau from 2011 [11].  However, 9	
concerns have been raised that misuse and abuse of opioid analgesics is not limited to those 10	
who access them via non-clinical routes, and has not been adequately addressed in 11	
individuals using them for legitimate medical needs [6,22,40].  12	
 13	
A recent review of opioid analgesic use in chronic pain patients identified substantial levels 14	
of problematic use [37].  Three types of problematic use were defined using statements from 15	
the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials and 16	
Analgesic, Anesthetic, and Addiction Clinical Trials, Translations, Innovations, 17	
Opportunities, and Networks [27,34]: 18	
• Misuse: use contrary to the directed pattern of use, regardless of harm or adverse 19	
effects; 20	
• Abuse: intentional use for a nonmedical purpose; 21	
• Addiction: pattern of continued use with experience of, or demonstrated potential for, 22	
harm. 23	
The authors estimated misuse was documented in 21-29% of patients, and addiction in 8-24	
12%.  Abuse could not be estimated due to insufficient data, but in the one suitable study 25	
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identified 8% of patients met abuse criteria.  However, the authors noted that most studies 26	
reviewed were from the USA, and raised the question of whether problematic opioid 27	
analgesic use is “a problem that is somehow uniquely relevant to the US”. 28	
 29	
There is evidence of problematic opioid analgesic use outside the USA, particularly in 30	
Europe and Australia.  Although heroin is the most frequently abused opioid in Europe, 31	
demand for treatment relating to problematic use of other opioids is increasing [13].  A 2012 32	
review identified opioid analgesics as one of the most commonly misused medicines in 33	
Europe, although the authors also noted the limited available data [9]. A more recent study 34	
estimated the prevalence of prescription opioid abuse as 13.7 per 10,000 individuals for 35	
France, 11.0 per 10,000 for Germany, and 10.7 per 10,000 for the United Kingdom (UK), but 36	
less than 1 per 10,000 individuals for Spain and Italy [33].  Similar statistics are unavailable 37	
for Australia, but a substantial increase in opioid analgesic prescriptions and opioid-related 38	
hospitalisations and deaths has occurred over the past decade, suggesting increasing levels of 39	
misuse and abuse [8].     40	
 41	
Using Global Drug Survey data from the USA, UK, France, Germany, and Australia we 42	
investigated whether misuse and abuse of opioid analgesics obtained via prescription varied 43	
between countries.  As polysubstance use involving illicit drugs and/or benzodiazepines is 44	
among the few consistent, strong predictors of problematic opioid analgesic use [9,32,36], we 45	
also investigated whether the association between this predictor and misuse or abuse varied 46	
between countries. 47	
 48	
 49	
 50	
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METHODS 51	
 52	
Sample 53	
Data were drawn from the 2015 Global Drug Survey (GDS), an annual online anonymous 54	
cross-sectional survey of licit and illicit drug use which ran from November 9th 2014 to 55	
January 3rd 2015 (www.globaldrugsurvey.com).  The GDS includes a core set of drug history 56	
and sociodemographic variables, with additional modules on specialist topics included or 57	
excluded each year.  Starting with a universal drug screen, the web-based survey then adjusts 58	
to ensure only sections relevant to each persons’ recent drug use experience are displayed.  59	
Further information on the range of topics covered is available at 60	
www.globaldrugsurvey.com/gds-surveys/survey-composition/.  For the analyses presented, 61	
data were drawn from a specialist module on prescription drugs, and the sociodemographic 62	
and universal drug screen sections. 63	
 64	
All participants confirmed they were aged ≥16 years and consented to analysis of the 65	
information they provided. Ethical approval was received from The Psychiatry, Nursing and 66	
Midwives Ethics subcommittee at Kings College, London.  The survey was  translated into 67	
10 languages and promoted in partnership with a range of media outlets including The 68	
Guardian, Zeit Online, la Repubblica, and Fairfax Media, and also distributed through 69	
Facebook, Twitter, social news website Reddit and drug discussion forums.  There are no 70	
exclusion criteria except being under the age of 16 years and thus it was open to any 71	
individual who wished to complete it.  The 2015 GDS was available in English, Danish, 72	
Flemish, French, German, Greek, Hungarian, Italian, Portuguese, Spanish, and Slovenian and 73	
distributed via media partners in Australia, Belgium, Denmark, France, Germany, Greece, 74	
Hungary, Ireland, Mexico, the Netherlands, New Zealand, Poland, Portugal, Slovenia, Spain, 75	
	 5	
Switzerland, the UK, and the USA.  However, as this was an online survey and it was 76	
advertised via social media, responses were also received from individuals residing in other 77	
countries.  GDS therefore recruits a non-probability sample and is not designed to determine 78	
the prevalence of drug behaviours in the general population. GDS is, however, an efficient 79	
way of gaining in-depth understanding of stigmatized behaviors that may not be well 80	
captured in more representative surveys.  Other publications provide further details on the 81	
utility, design, and limitations of the Global Drug Survey [4,7,26,39]. 82	
 83	
In total, the 2015 GDS received responses from over 100,000 participants from 175 84	
countries, with 31 countries contributing 100 or more responses.  Our original intention was 85	
to analyse data from the USA, Australia, and the five European countries examined by Shei 86	
et al. [33] (UK, France, Germany, Spain, and Italy).  However, we could only include 87	
countries with enough overall participants to ensure a sufficient sample of prescription opioid 88	
users for the multi-level analyses (described below).  Unfortunately, less than 1,000 89	
responses were received from participants resident in Italy and Spain so we could not include 90	
these countries in the analyses.  Thus the analysis sample was defined as GDS on participants 91	
from Australia, France, Germany, the UK and the USA who had used prescription codeine, 92	
hydrocodone, oxycontin, or tramadol in the past 12 months. The relative frequency of 93	
prescribing of these opioid analgesics differs between countries: codeine and tramadol are 94	
more commonly prescribed in the UK, France, and Germany [1,16,31] whereas oxycodone 95	
and hydrocodone are more commonly prescribed in the USA [38].  In Australia, codeine is 96	
prescribed most frequently, followed by tramadol and oxycodone which are prescribed at 97	
similar frequencies [19].  98	
 99	
	 6	
 100	
Measures 101	
Demographic covariates  102	
Information was collected on gender, age, and highest educational qualification (high school, 103	
college diploma, undergraduate, postgraduate).   104	
 105	
Drug use   106	
Participants were asked "Have you used any of the following drugs in the last year?" and 107	
presented with a list of illicit drugs and licit drugs (including opioid analgesics and 108	
benzodiazepines).  The following questions were revealed dynamically for each opioid 109	
analgesic for which they endorsed past-year use.  110	
 111	
Methods of access 112	
Participants were asked "Which of the following methods have you used to obtain it [specific 113	
medication]?" with the following options: Prescribed to you; Given to you by a friend; 114	
Bought by you from a dealer; Bought by you on the internet (multiple selections possible).   115	
 116	
Ease of access to a prescription  117	
Participants were asked “How easy would it be for you get it [drug] prescribed to you within 118	
the next 7 days?” selecting one option from: Very easy; Easy; Possible; Difficult; Very 119	
difficult. Responses were collapsed into a binary variable indicating “Very easy”' or “Easy”' 120	
responses versus other responses. 121	
 122	
 123	
 124	
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 125	
Opioid analgesic misuse and abuse  126	
Misuse and abuse were defined following Vowles et al. [37].  In our data, misuse was coded 127	
if participants endorsed one or more of the following responses to “If it [drug] was prescribed 128	
to you in the last 12 months have you found yourself…”: 129	
• taking more than was prescribed; 130	
• trying to get hold of extra medication; 131	
• being unable cut down or stop using it; 132	
• feeling physically and/or emotionally unwell when using less or stopping use; 133	
• ever overdosed. 134	
Abuse was coded if participants endorsed one or more of the following responses to the same 135	
question: 136	
• mixing it with other drugs to enhance the drug effect; 137	
• mixing it with alcohol to enhance the drug effect. 138	
Abuse was also coded if participants endorsed the option “getting high” when responding to 139	
the question “In the last year have you taken this medication to achieve these desirable 140	
objectives…”. 141	
Misuse and abuse variables were derived separately for each opioid analgesic, but as some 142	
participants endorsed the use of more than one opioid analgesic, these data were also 143	
combined to create two variables indicating misuse of at least one opioid analgesic and abuse 144	
of at least one opioid analgesic. 145	
 146	
Polysubstance use 147	
Using the screening question “Have you used any of the following drugs in the past year?”, 148	
we identified participants who endorsed use of benzodiazepines (with or without a 149	
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prescription) or the following illicit drugs: cannabis (hydroponic, herbal, resin, or oil), 150	
ecstasy (pills or powder), cocaine, crack, amphetamine, methamphetamine, mephedrone, or 151	
heroin.  For descriptive purposes, we used these data to create a categorical variable 152	
indicating the following mutually exclusive patterns of substance use: no use of illicit drugs 153	
or benzodiazepines in the past year; use of one or more illicit drugs only; use of 154	
benzodiazepines only; use of one or more illicit drugs and benzodiazepines (combined use).  155	
For analytical purposes we created two binary variables, one indicating use of illicit drugs in 156	
the past year and other indicating use of benzodiazepines in the past year.  157	
 158	
Statistical analysis 159	
Sample characteristics were summarised using standard descriptive statistics.  Multivariable 160	
analyses were conducted using multi-level (i.e. mixed effects) binary logistic regression 161	
models to allow for clustering of participants within countries, and estimation of the 162	
variability in misuse and abuse due to country of residence.  These models were used to 163	
investigate the association between polysubstance use and (i) misuse of at least one 164	
prescription opioid analgesic; (ii) abuse of at least one prescription opioid analgesic.  Age, 165	
gender, education level, and employment status were included as covariates.   166	
 167	
Models included a random country-level intercept to allow for between-country variation in 168	
risk of opioid analgesic misuse and abuse.  The effect of country of residence was quantified 169	
using the intraclass correlation and median odds ratio [24].  Illicit drug use and 170	
benzodiazepine use were initially modelled as fixed effects with an interaction term; random 171	
slope models were then fitted to evaluate whether the associations between misuse/abuse and 172	
illicit drug use and benzodiazepine use varied by country of residence.  The models provide 173	
odds ratio (OR) estimates for the association between polysubstance use and misuse or abuse, 174	
	 9	
holding country of residence constant [15,17].   The covariates age, gender, education level, 175	
and employment were included as fixed effects.  Models were fitted via maximum likelihood 176	
with difference in model fit evaluated using likelihood ratio chi-squared tests.  As the 177	
alternative hypotheses regarding variances are technically one-sided, halving the p-value for 178	
these tests has been suggested [35]; we report the standard p-values but consider this 179	
modification when interpreting results.  Analyses were conducted in R version 3.3.1 (Bug in 180	
Your Hair) [29] using the lme4 package for multi-level models, with 95% confidence 181	
intervals (CI) for the final model parameter estimates obtained using bootstrapping with 4000 182	
replicates per model [5]. 183	
 184	
RESULTS 185	
 186	
Sample description 187	
The analysis sample consisted of 5,670 participants who had used codeine, hydrocodone, 188	
oxycontin, or tramadol in the past 12 months and had obtained it via a prescription (see Table 189	
1).  Overall, 45.8% of the sample were female with an average age of 33.2 years (standard 190	
deviation 13.8 years).  Participants were relatively evenly distributed across the education 191	
categories: 24.9% reported highschool as their highest qualification, 22.2% reported a college 192	
diploma, 28.7% reported an undergraduate degree, and 22.6% reported a postgraduate 193	
degree.  Almost two thirds (64.1%) were employed.  The analysis sample differs from the 194	
total sample of GDS participants from the five countries in that the full sample has a lower 195	
percentage of women (37%), lower average age (30.0 years), fewer participants with a 196	
postgraduate qualification (14.9%), and a lower level of employment (60.7%).   197	
 198	
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The analysis sample included similar numbers of participants from each of the five countries, 199	
although there were slightly fewer from Germany.  Use of particular opioid analgesics 200	
differed by country of residence, as expected given regional differences in prescribing 201	
practices.  Codeine was the most frequently used drug by participants resident in Australia 202	
(91.2%), France (90.6%), Germany (77.7%), and the United Kingdom (92.8%), while 203	
hydrocodone was most commonly used by US participants (63.9%).  Overall, 45.4% of the 204	
sample had not used benzodiazepines or illicit drugs in the past year.  Past-year illicit drug 205	
use was reported by a further 42.3%, with 4.4% having used only benzodiazepines in the past 206	
year, and 7.9% endorsing use of both benzodiazepines and illicit drugs.  Of those who had 207	
used illicit drugs in the past year more than half (57.0%) had only used cannabis, with ecstasy 208	
(12.2%) and cocaine (10.0%) the next most frequently used single drugs.  Only 2% (N=58) of 209	
illicit drug users had used heroin in the past year.  Of those who had used benzodiazepines in 210	
the past year, 61.7% reported obtaining them via prescription. 211	
 212	
Access to opioid analgesics 213	
Obtaining a prescription for these opioid analgesics within seven days was perceived as being 214	
easier for codeine (39.4% reported it would be “very easy” or “easy”) and tramadol (46.4%), 215	
compared to hydrocodone (18.4%) and oxycontin (25.1%).  Obtaining any of these opioid 216	
analgesics without a prescription, via a dealer or the internet, was very uncommon (see 217	
Figure 1).  Only about 1% of codeine and tramadol users reported obtaining these drugs via a 218	
dealer or the internet.  For hydrocodone and oxycontin the percentage of participants who 219	
also reported obtaining the drug from a dealer was higher (7.0% and 5.7% respectively), but 220	
the percentage buying these drugs via the internet was less than 1%.  Being given these drugs 221	
by friends was a more common route for obtaining them without a prescription (reported by 222	
6.7% to 23.2% of participants, depending on drug). 223	
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 224	
 225	
Level of misuse and abuse of opioid analgesics 226	
Between 8% and 22% of participants who had not used any illicit drugs or benzodiazepines 227	
in the past year reported misuse or abuse of codeine, hydrocodone, oxycontin, or tramadol 228	
(see Table 2).  Overall, compared to those who had not used any other substances, 229	
approximately twice as many participants who had used illicit drugs only, or benzodiazepines 230	
only, reported misuse of any opioid analgesic (26.8% and 33.5% respectively compared to 231	
14.7%).  Three times as many participants who engaged in polysubstance use reported misuse 232	
(45.7%).  Participants who only used illicit drugs, or only used benzodiazepines, were 233	
approximately three times as likely to report abuse of opioid analgesics compared to those 234	
who used no other substances (23.9% and 27.8% respectively compared to 8.8%).  Almost 235	
five times as many participants who endorsed polysubstance use reported abuse of opioid 236	
analgesics (43.7%).  The percentage of participants reporting misuse and abuse differed by 237	
country of residence; Australian participants were the least likely to report misuse and abuse 238	
(17.0% and 12.5% respectively), while participants from the USA were most likely (28.2% 239	
and 27.7% respectively).  Similar percentages of participants from France and the UK 240	
reported misuse (21.5% and 21.0% respectively) and abuse (15.6% and 16.6% respectively).  241	
German participants reported a level of misuse similar to participants from the USA (27.5%), 242	
but were less likely to report abuse (20%). 243	
 244	
Association between polysubstance use and misuse/abuse of prescription opioid 245	
medications 246	
We first fitted “empty” multi-level models to investigate how much variability in misuse and 247	
abuse of opioid analgesics could be explained by participant country of residence [25].  For 248	
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both models, likelihood ratio tests comparing fixed effects and random intercept models 249	
indicated that there was significance variance explained by the between-country effect on 250	
misuse (!"#=34.98, p <0.0001) and abuse (!"#=73.53, p <0.0001).  However, the intraclass 251	
correlations and median odds ratios for both models were small.  The percentage of variance 252	
in misuse explained by country of residence was only 1.5% and the median odds ratio was 253	
1.12, while the percentage of variance in abuse explained was 2.8% and the median odds 254	
ratio was 1.34. 255	
 256	
For the opioid analgesic misuse model, allowing the effects of illicit drug use and 257	
benzodiazepine use to vary by country of residence did not significantly improve model fit 258	
(!$#=8.53, p = 0.13) and they were therefore included as fixed effects in the full multivariable 259	
model.  Based on the full multivariable model (see Table 3), use of both illicit drugs and 260	
benzodiazepines was associated with over four-fold greater odds of opioid analgesic misuse 261	
compared to not using any additional substances (OR 4.36, 95% CI 3.29 – 5.93), while use of 262	
benzodiazepines only was associated with three-fold greater odds (OR 3.37, 95% CI 2.25 – 263	
5.25).  However, both were more strongly associated with misuse than use of illicit drugs 264	
only (OR 1.79, 95% CI 1.41 – 2.37).     265	
 266	
Allowing the effects of illicit drug use and benzodiazepine use to vary by country of 267	
residence did significantly improve the fit of the model for opioid analgesic abuse (!$#=13.26, 268	
p = 0.02).  The effect of illicit drug use on abuse varied considerably more between country 269	
of residence than the effect of benzodiazepine use (see Table 3).  Covariance with the 270	
intercept was negative for both illicit drug use and benzodiazepine use, suggesting the 271	
association of polysubstance use with abuse is weaker in countries with higher levels of 272	
abuse.  The fixed effects estimates for the relationship between polysubstance use and opioid 273	
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analgesic abuse were stronger than those for misuse, but displayed the same pattern. The 274	
odds of opioid analgesic abuse were highest for participants using both illicit drugs and 275	
benzodiazepines compared to those not using any additional substances (OR 6.49, 95% CI 276	
4.0 – 10.48), over four-fold higher for those using benzodiazepines only (OR 4.79, 95% CI 277	
2.70 – 8.95), and over two-folder higher for those using only illicit drugs (OR 2.46, 95% CI 278	
1.75 – 3.60). 279	
 280	
DISCUSSION 281	
 282	
In this sample of individuals from the USA, UK, France, Germany, and Australia who had 283	
used opioid medications obtained via prescription in the past year, 1 in 4 individuals reported 284	
misuse of any opioid analgesics, and approximately 1 in 5 individuals reported abuse.  285	
Although these data come from a non-probability sample, this level of opioid medication 286	
misuse is similar to that obtained from a recent systematic review of misuse, abuse, and 287	
addiction in chronic pain patients [37], and represents one of the few available estimates of 288	
level of abuse of these drugs.  Misuse and abuse differed between those who had and had not 289	
used illicit drugs and/or benzodiazepines in the past year; approximately 1 in 7 non-users 290	
reported misuse and 1 in 11 reported abuse, compared to approximately 1 in 3 users reporting 291	
misuse or abuse.   292	
 293	
The multi-level models fitted indicated that country of residence only accounted for a small 294	
proportion of the variance in opioid analgesic misuse and abuse.  Holding the effect of 295	
country of residence constant and adjusting for sociodemographic factors, combined use of 296	
illicit drugs and benzodiazepines was associated with four-fold greater odds of opioid 297	
analgesic misuse and six-fold greater odds of abuse compared to not using either drug. There 298	
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were no significant between-country differences in the effect of either illicit drug use or 299	
benzodiazepine use on misuse.  However, the association between both types of 300	
polysubstance use and opioid analgesic abuse varied by country of residence, with this being 301	
more pronounced for illicit drug use.  Thus, although these results provide limited support for 302	
the idea that misuse and abuse of these opioid analgesics is a phenomenon specific to the 303	
USA, we did find evidence that the relationship between some risk factors and opioid 304	
analgesic abuse may differ between countries.   305	
 306	
The importance of benzodiazepine use in the context of problematic use of opioid analgesics 307	
is perhaps unsurprising given that the combined use of these drugs is well documented [21] 308	
and benzodiazepine use is a risk factor for opioid misuse [9] and overdose [20,41].  As those 309	
using both opioids and benzodiazepines are at increased risk of fatal overdose, this finding 310	
highlights the need for clinicians to be vigilant in identifying risk behaviours in those in 311	
receipt of both medication classes. Despite most clinical guidelines cautioning against 312	
concomitant prescription, there may be genuine indications such as managing co-existent 313	
anxiety or augmenting analgesic effects [18].  In our sample of prescription opioid users, just 314	
over 60% of benzodiazepine users reported also obtaining this drug via a prescription. 315	
However, prescription opioids and benzodiazepines are two of the drugs most commonly 316	
obtained via “doctor shopping” [20,23], so it is possible that in many cases a prescription for 317	
one drug was obtained without the clinician knowing the patient already held a prescription 318	
for the other. Regional differences in family doctor registration and prescription drug 319	
monitoring programmes, which can help prevent doctor shopping, could account for some of 320	
the between-country variation we observed in the association between polysubstance use and 321	
prescription opioid abuse [2]. 322	
 323	
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The interplay between illicit drugs, benzodiazepines, and opioid analgesics is less well 324	
characterised.  As only 2% of those who had used illicit drugs in the past year were heroin 325	
users it is unlikely that the results were driven by use of opioid analgesics as a substitute for 326	
heroin.  For 57% of participants using both illicit drugs and opioid analgesics, cannabis was 327	
the only illicit drug they had used in the past year.  Cannabis use has been identified as a risk 328	
factor for opioid analgesic misuse in chronic pain patients [30], and previous research 329	
identified a pattern of polysubstance use involving cannabis and both opioid analgesics and 330	
benzodiazepines which was associated with increased risk of mental illness, another risk 331	
factor for opioid misuse and abuse [10,12,26,32].  However, efforts to develop risk prediction 332	
models for problematic opioid analgesic use have generally grouped all substance use 333	
disorders together [10,12].  More research is needed to investigate the interaction between 334	
different illicit drugs and benzodiazepines to better understand how use of these drugs 335	
increases risk of problematic opioid analgesic use. 336	
 337	
One limitation of these results is that we used data on past year drug use, which is not 338	
necessarily the same as simultaneous use within a short time frame (e.g. 24 hours), although 339	
Quek et al. [28] found that most people reporting use of multiple drugs in the past year also 340	
reported simultaneous use of those drugs.  The other main limitation is that these data were 341	
collected via an anonymous online survey using a non-probability sampling strategy.  It is not 342	
possible to estimate response rates for this type of sampling strategy and it cannot be 343	
considered to provide a representative sample of individuals from the countries included, so 344	
the results should not be generalised to the broader populations from which they are drawn.  345	
Participants in this type of study are likely to be younger, male, urban-dwelling, endorse use 346	
of illicit drugs, and have completed more years of formal education than participants from a 347	
representative sample [3].  However, although the recruitment strategy may not provide a 348	
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representative sample, the fact that it was anonymous and did not involve a participant’s 349	
clinical care provider may mean that people were more likely to disclose both misuse and 350	
abuse of opioid analgesics, and use of illicit drugs.  Additionally, this data set provided a 351	
large sample of individuals who had obtained opioid analgesics via a prescription across 352	
several countries.  Given the noted scarcity of data on problematic use of opioid analgesics 353	
from outside the USA [9,33,37], these data are useful for exploring this phenomenon and 354	
generating new research questions.  Regardless, the findings presented here should be 355	
investigated further in representative samples from the USA, UK, France, Germany, and 356	
Australia.  357	
 358	
In conclusion, levels of opioid analgesic misuse and abuse appear to be higher in those who 359	
engage in polysubstance use involving illicit drugs and/or benzodiazepines, but there are 360	
substantial numbers of individuals who are not polysubstance users and engage in misuse 361	
and/or abuse.  Policies and interventions have been developed on the assumption that there 362	
are two distinct populations of people, one that uses only medication prescribed to them and 363	
are compliant with dosing instructions, and another group who obtain prescription opioids via 364	
non-clinical routes, use other licit and/or illicit drugs, and engage in misuse and abuse. This 365	
distinction does not accurately reflect the reality of prescription opioid use, and highlights the 366	
importance of universal approaches to patient education, prescription and patient 367	
monitoring.  While doctors remain the major source for these drugs, they will need to be 368	
targeted and engaged as the pivotal sites for change. Differences between the USA and other 369	
developed countries in relation to healthcare regulatory systems, patient expectations, and 370	
direct-to-consumer advertising have contributed to the substantially greater magnitude of 371	
problematic opioid analgesic use in the USA [2,14,38]. However, the issue of misuse and 372	
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abuse amongst those who are prescribed opioid analgesics appears to be a problem that 373	
warrants attention on an international scale. 374	
 375	
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Figure 1: Venn diagrams showing sources for obtaining (a) codeine, (b) hydrocodone, (c) oxycontin, (d) tramadol.  Given numbers indicate that 
participants obtained prescription opioid analgesics from family and/or friends. 
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Table 1: Socio-demographic characteristics and patterns of drug use of analysis sample 
 
Variable Categories 
Total  
(N = 5670)   
Australia  
(N = 1013)   
France  
(N = 1258)   
Germany  
(N = 866)   
United Kingdom 
(N = 1199)   
United States  
(N = 1334) 
    N/mean %/S.D.   N/mean %/S.D.   N/mean %/S.D.   N/mean %/S.D.   N/mean %/S.D.   N/mean %/S.D. 
Sex Female 2598 45.8 
 
459 45.3 
 
597 47.5 
 
354 40.9 
 
486 40.5 
 
702 52.6 
 
Male 3072 54.2 
 
554 54.7 
 
661 52.5 
 
512 59.1 
 
713 59.5 
 
632 47.4 
Age Mean 33.2 13.8 
 
39.1 14.7 
 
29.1 10.2 
 
32.2 12.8 
 
34.0 13.0 
 
32.6 15.8 
Education Highschool 1410 24.9 
 
293 28.9 
 
181 14.4 
 
242 27.9 
 
225 18.8 
 
469 35.2 
 
College diploma 1256 22.2 
 
145 14.3 
 
315 25.0 
 
276 31.9 
 
279 23.3 
 
241 18.1 
 
Undergraduate 1626 28.7 
 
291 28.7 
 
234 18.6 
 
256 29.6 
 
421 35.1 
 
424 31.8 
 
Postgraduate 1280 22.6 
 
271 26.8 
 
511 40.6 
 
82 9.5 
 
256 21.4 
 
160 12.0 
 
Missing 98 1.7 
 
13 1.3 
 
17 1.4 
 
10 1.2 
 
18 1.5 
 
40 3.0 
Employment Yes 3635 64.1 
 
722 71.3 
 
728 57.9 
 
545 62.9 
 
791 66.0 
 
849 63.6 
 
No 1993 35.1 
 
281 27.7 
 
518 41.2 
 
314 36.3 
 
402 33.5 
 
478 35.8 
 
Missing 42 0.7 
 
10 1.0 
 
12 1.0 
 
7 0.8 
 
6 0.5 
 
7 0.5 
Opioid analgesic Codeine 4243 74.8 
 
924 91.2 
 
1140 90.6 
 
673 77.7 
 
1113 92.8 
 
393 29.5 
 
Hydrocodone 887 15.6 
 
8 0.8 
 
5 0.4 
 
8 0.9 
 
14 1.2 
 
852 63.9 
 
Oxycontin 526 9.3 
 
152 15.0 
 
6 0.5 
 
55 6.4 
 
11 0.9 
 
302 22.6 
 
Tramadol 729 12.9 
 
82 8.1 
 
203 16.1 
 
168 19.4 
 
166 13.8 
 
110 8.2 
Polysubstance use None 2575 45.4 
 
576 56.9 
 
448 35.6 
 
519 59.9 
 
595 49.6 
 
437 32.8 
 
Illicit only 2398 42.3 
 
272 26.9 
 
704 56.0 
 
285 32.9 
 
504 42.0 
 
633 47.5 
 
Benzodiazepine only 248 4.4 
 
82 8.1 
 
43 3.4 
 
23 2.7 
 
30 2.5 
 
70 5.2 
  Combined 449 7.9   83 8.2   63 5.0   39 4.5   70 5.8   194 14.5 
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Table 2: Levels of opioid analgesic misuse and abuse by polysubstance use.  Percentages are shown for each opioid analgesic and for misuse or 
abuse of at least one. 
 
Variable Opioid 
analgesic 
Total  No substance 
use 
 Illicit only  Benzodiazepines 
only 
 Combined 
    N %   N %   N %   N %   N % 
Misuse Codeine 838 19.8  265 12.9  409 23.3  54 32.0  110 41.7 
 Hydrocodone 253 28.5  48 17.1  122 29.5  20 38.5  63 44.4 
 Oxycontin 148 28.1  29 14.1  67 32.2  16 43.2  36 48.0 
 Tramadol 239 32.8  65 22.6  121 39.8  12 20.7  41 51.9 
 Any 1308 23.1  378 14.7  642 26.8  83 33.5  205 45.7 
Abuse Codeine 641 15.1  159 7.7  335 19.1  46 27.2  101 38.3 
 Hydrocodone 249 28.1  24 8.6  135 32.7  16 30.8  74 52.1 
 Oxycontin 132 25.1  21 10.2  65 31.3  13 35.1  33 44.0 
 Tramadol 180 24.7  40 13.9  98 32.2  10 17.2  32 40.5 
  Any 1064 18.8   226 8.8   573 23.9   69 27.8   196 43.7 
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Table 3: Estimates from multi-level models of associations between opioid analgesic misuse and abuse, polysubstance use, and 
sociodemographic characteristics.  95% confidence intervals (C.I.) were obtained via bootstrapping.  
 
Variable Value Misuse 
 
Abuse 
    Beta 95% C.I. P   Beta 95% C.I. P 
Fixed effects 
        Illicit drug use No  Ref. 
   
Ref. 
  
 
Yes 0.58 0.35 to 0.87 <0.0001 
 
0.90 0.57 to 1.29 <0.0001 
Benzodiazepine use No  Ref. 
   
Ref. 
  
 
Yes 1.22 0.81 to 1.66 <0.0001 
 
1.57 1 to 2.2 <0.0001 
Illicit x benzodiazepine interaction 
 
-0.33 -0.96 to 0.31 0.08 
 
-0.59 -1.6 to 0.3 0.004 
Age 
 
-0.33 -0.45 to -0.22 <0.0001 
 
-0.47 -0.63 to -0.32 <0.0001 
Sex Female Ref. 
   
Ref. 
  
 
Male 0.31 -0.07 to 0.72 <0.0001 
 
0.59 0.06 to 1.12 <0.0001 
Education Highschool Ref. 
   
Ref. 
  
 
College diploma -0.20 -0.49 to 0.14 <0.001 
 
-0.21 -0.45 to 0.01 0.04 
 
Undergraduate degree -0.33 -0.57 to -0.05 <0.001 
 
-0.31 -0.6 to -0.09 0.002 
 
Postgraduate degree -0.40 -0.7 to -0.1 <0.001 
 
-0.47 -0.88 to -0.14 <0.001 
Employment No  Ref. 
   
Ref. 
  
 
Yes -0.21 -0.39 to -0.06 0.002 
 
-0.27 -0.57 to -0.03 <0.001 
Random effects 
        Intercept variance 
 
0.03 0 to 0.08 
  
0.03 0.01 to 0.19 
 Illicit drug variance 
 
N/A 
   
0.14 0.01 to 0.35 
 Benzodiazepines variance 
 
N/A 
   
0.004 0.01 to 0.16 
 Intercept - illicit covariance 
 
N/A 
   
-0.02 -0.17 to 0.05 
 Intercept - benzodiazepines covariance N/A 
   
-0.01 -0.11 to 0.04 
 Illicit - benzodiazepines covariance   	N/A	 		   		 -0.01 -0.12 to 0.08   
 
